SCHEMBL23966706

SCHEMBL23966706

CC1(c2cc(NC(=O)Oc3ccccc3)on2)COC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.41
MAPT P10636 4/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KMT2A Q03164 5/20 0.40
GAA P10253 3/20 0.40
MEN1 O00255 3/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
CYP1A2 P05177 1/20 0.40
FAAH O00519 3/20 0.40
KDM4E B2RXH2 2/20 0.40
GLA P06280 1/20 0.40
HPGD P15428 1/20 0.40
ATM Q13315 1/20 0.40
IDO1 P14902 1/20 0.40
MAOB P27338 1/20 0.40
SCD O00767 1/20 0.39
SCD5 Q86SK9 1/20 0.39
CCNE1 P24864 1/20 0.39
CDK2 P24941 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11966200 0.91 FAAH (0.43) ALDH1A1MAPTSMN1; SMN2KMT2AGAA
SCHEMBL23966628 0.89 FAAH (0.44) ALDH1A1MAPTSMN1; SMN2KMT2AGAA
SCHEMBL23966917 0.80 FAAH (0.46) ALDH1A1MAPTCYP1A2FAAHTRPV1
SCHEMBL1012030 0.78 BRAF (0.49) ALDH1A1MAPTCYP1A2FAAHTRPV1
SCHEMBL1895964 0.78 ALDH1A1 (0.53) ALDH1A1MAPTSMN1; SMN2KMT2AGAA
SCHEMBL5224012 0.77 RAB9A (0.48) ALDH1A1MAPTSMN1; SMN2KMT2AGAA
SCHEMBL1013412 0.77 MAPT (0.60) ALDH1A1MAPTSMN1; SMN2KMT2AGAA
SCHEMBL1011915 0.76 ALDH1A1 (0.52) ALDH1A1MAPTSMN1; SMN2KMT2AGAA
SCHEMBL11966202 0.75 ALDH1A1 (0.45) ALDH1A1MAPTSMN1; SMN2KMT2AGAA
SCHEMBL1013171 0.74 ALDH1A1 (0.56) ALDH1A1MAPTKMT2AGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12091413-B2 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2024-09-17 US disclosed
EP-4146348-B1 INHIBITORS OF NEK7 KINASE HALIA THERAPEUTICS INC (US) 2024-07-03 EP disclosed
US-20230416259-A1 INHIBITORS OF NEK7 KINASE HALIA THERAPEUTICS INC (US) 2023-12-28 US disclosed
US-11713321-B2 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2023-08-01 US disclosed
US-11713321-B2 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2023-08-01 US disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 US disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 US disclosed
EP-4146348-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. (US) 2023-03-15 EP disclosed
US-20220064173-A1 INHIBITORS OF NEK7 KINASE HALIA THERAPEUTICS INC (US) 2022-03-03 US disclosed
WO-2021242505-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. (US) 2021-12-02 WO disclosed
US-20210355130-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. 2021-11-18 US disclosed
US-11161852-B1 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2021-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210355130-A1 INHIBITORS OF NEK7 KINASE NEK7, NEK1, NEK5 ALDH1A1 4354/4885MAPT 1210/4885SMN1; SMN2 3247/4885
US-11713321-B2 Inhibitors of NEK7 kinase NEK7, NEK1, NEK5 ALDH1A1 4354/4885MAPT 1210/4885SMN1; SMN2 3247/4885
US-12091413-B2 Inhibitors of NEK7 kinase NEK7, NEK1, NEK5 ALDH1A1 4354/4885MAPT 1210/4885SMN1; SMN2 3247/4885
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME NEK7, NLRP3, NOD1 ALDH1A1 4542/4885MAPT 436/4885SMN1; SMN2 3670/4885
US-11161852-B1 Inhibitors of NEK7 kinase NEK7, NEK1, NEK5 ALDH1A1 4354/4885MAPT 1210/4885SMN1; SMN2 3247/4885
US-20230416259-A1 INHIBITORS OF NEK7 KINASE NEK7, NEK1, NEK5 ALDH1A1 4354/4885MAPT 1210/4885SMN1; SMN2 3247/4885
US-20220064173-A1 INHIBITORS OF NEK7 KINASE NEK7, NEK1, NEK5 ALDH1A1 4354/4885MAPT 1210/4885SMN1; SMN2 3247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.